VTI-1002
/ viDA
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2019
Granzyme B-mediated cleavage of hemidesmosomal proteins contributes to blister formation in epidermolysis bullosa acquisita
(SID 2019)
- "The in vitro results were rescued with our newly developed GzmB inhibitor, VTI-1002 (n=3). In summary, GzmB contributes to blister formation in EBA through the cleavage of hemidesmosomal proteins and provides evidence validating GzmB as a therapeutic target for the treatment of EBA and other blistering diseases."
1 to 1
Of
1
Go to page
1